Average rating
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Star rating
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Authors
Schneider, Christian KBorg, John J
Ehmann, Falk
Ekman, Niklas
Heinonen, Esa
Ho, Kowid
Hoefnagel, Marcel H
van der Plas, Roeland Martijn
Ruiz, Sol
van der Stappen, Antonius J
Thorpe, Robin
Tiitso, Klara
Tsiftsoglou, Asterios S
Vleminckx, Camille
Waxenecker, Guenter
Welin, Mats
Weise, Martina
Trouvin, Jean-Hugues
Issue Date
2012-08
Metadata
Show full item recordCitation
In support of the European Union biosimilar framework. 2012, 30 (8):745-8; author reply 748-9 Nat. Biotechnol.Journal
Nature biotechnologyDOI
10.1038/nbt.2322PubMed ID
22871707Type
ArticleLanguage
enISSN
1546-1696ae974a485f413a2113503eed53cd6c53
10.1038/nbt.2322
Scopus Count
The following license files are associated with this item:
Related articles
- Clinical comparability and European biosimilar regulations.
- Authors: Schellekens H, Moors E
- Issue date: 2010 Jan
- Drug marketing exclusivity under United States and European Union law.
- Authors: Junod V
- Issue date: 2004
- Biosimilars: where we were and where we are.
- Authors: Challand R, Gorham H, Constant J
- Issue date: 2014
- Biosimilars: policy, clinical, and regulatory considerations.
- Authors: Gottlieb S
- Issue date: 2008 Jul 15
- Paediatric oral biopharmaceutics: key considerations and current challenges.
- Authors: Batchelor HK, Fotaki N, Klein S
- Issue date: 2014 Jun